Deferasirox var ikke carcinogent, når det blev administreret til rotter i et 2- års studie og transgene p53+ / - heterozygote mus i et 6- måneders studie.
Deferasirox was not carcinogenic when administered to rats in a 2-year study and transgenic p53+/ - heterozygous mice in a 6-month study.